Nabumetone

Rheumatoid Arthritis, Osteoarthritis
Treatment
3 FDA approvals
20 Active Studies for Nabumetone

What is Nabumetone

NabumetoneThe Generic name of this drug
Treatment SummaryNabumetone is a non-steroidal anti-inflammatory drug (NSAID) used to reduce inflammation and pain. It is a pro-drug that is converted into a 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite that acts as a potent COX inhibitor, similar to naproxen. It was first approved by the FDA in 1991 under the trade name Relafen. Although it has slightly reduced GI toxicity due to its cyclooxygenase-2 selectivity, it can still cause adverse effects in the gastrointestinal tract.
Relafenis the brand name
image of different drug pills on a surface
Nabumetone Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Relafen
Nabumetone
1993
192

Approved as Treatment by the FDA

Nabumetone, otherwise called Relafen, is approved by the FDA for 3 uses including Osteoarthritis (OA) and Rheumatoid Arthritis .
Osteoarthritis (OA)
Rheumatoid Arthritis
Osteoarthritis

Effectiveness

How Nabumetone Affects PatientsNabumetone is a type of drug called a nonsteroidal anti-inflammatory drug (NSAID) that is used as a painkiller. It helps reduce pain by reducing the sensitivity of nerve endings to painful or uncomfortable stimuli. It also helps reduce inflammation and fever by blocking the release of substances that cause inflammation and by affecting the body's temperature regulation system in the brain. However, it can also have adverse effects such as decreased blood flow to the kidneys and increased risk of ulcers and thrombosis.
How Nabumetone works in the bodyNabumetone works by blocking two enzymes, COX-1 and COX-2. This prevents the production of prostaglandins, which are molecules that help to mediate pain sensitivity, inflammation, and fever. It also helps to reduce the amount of neurotransmitters released from nerves, which reduces pain signals. Prostaglandins also regulate blood flow to the kidneys and protect the stomach from acid, so blocking them can lead to adverse effects like kidney problems or ulcers. Finally, it can lead to an imbalance of platelet aggregation, which can increase the risk of blood clots.

When to interrupt dosage

The advised measure of Nabumetone is contingent upon the diagnosed condition. The amount of dosage shifts as indicated by the technique of delivery noted in the table underneath.
Condition
Dosage
Administration
Rheumatoid Arthritis
750.0 mg, , 500.0 mg, 1000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Oral; Topical, Kit - Oral; Topical
Osteoarthritis
750.0 mg, , 500.0 mg, 1000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Oral; Topical, Kit - Oral; Topical

Warnings

Nabumetone has eleven contraindications, so it should be avoided in individuals with any of the conditions specified in the table below.Nabumetone Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
NSAID-Induced Asthma
Do Not Combine
Liver Disease
Do Not Combine
Rhinitis
Do Not Combine
Coronary Artery Bypass Grafting
Do Not Combine
Renal Insufficiency
Do Not Combine
Nasal Polyps
Do Not Combine
Gastrointestinal Diseases
Do Not Combine
Liver Diseases
Do Not Combine
Peptic Ulcer
Do Not Combine
Peptic Ulcer
Do Not Combine
There are 20 known major drug interactions with Nabumetone.
Common Nabumetone Drug Interactions
Drug Name
Risk Level
Description
Macimorelin
Major
The therapeutic efficacy of Macimorelin can be decreased when used in combination with Nabumetone.
Methotrexate
Major
The serum concentration of Methotrexate can be increased when it is combined with Nabumetone.
Mifamurtide
Major
The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Nabumetone.
Neomycin
Major
The risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Neomycin.
Omacetaxine mepesuccinate
Major
The risk or severity of bleeding can be increased when Nabumetone is combined with Omacetaxine mepesuccinate.
Nabumetone Toxicity & Overdose RiskThe lowest toxic dose of nabumetone in mice is 4290mg/kg when taken orally and 2380mg/kg when taken intraperitoneally. In rats, the lowest toxic dose is 3880mg/kg when taken orally, 1520mg/kg when taken intraperitoneally, and >10g/kg when taken subcutaneously. Signs and symptoms of an overdose include lethargy, drowsiness, nausea, vomiting, and abdominal pain. Serious but rare effects of an overdose include GI bleeding, high blood pressure, kidney damage, respiratory depression, and coma. Activated charcoal and/
image of a doctor in a lab doing drug, clinical research

Nabumetone Novel Uses: Which Conditions Have a Clinical Trial Featuring Nabumetone?

75 active trials are currently assessing the potential of Nabumetone to treat Osteoarthritis (OA).
Condition
Clinical Trials
Trial Phases
Rheumatoid Arthritis
54 Actively Recruiting
Not Applicable, Phase 4, Phase 3, Phase 2, Phase 1
Osteoarthritis
0 Actively Recruiting

Nabumetone Reviews: What are patients saying about Nabumetone?

5Patient Review
11/16/2015
Nabumetone for Joint Damage causing Pain and Loss of Function
I'm really pleased with how this medication has helped me. I've only been taking it for a week and feel so much better. No negative effects that I can tell.
5Patient Review
11/26/2020
Nabumetone for Joint Damage causing Pain and Loss of Function
I don't have any problems taking NSAIDs, and this combined with Tramadol helps to lessen the pain of arthritis.
5Patient Review
7/26/2016
Nabumetone for Rheumatoid Arthritis
I've been taking this prescription for over ten years with no problems whatsoever. I have found that if I go more than two days without it, the pain comes back.
5Patient Review
4/30/2016
Nabumetone for Joint Damage causing Pain and Loss of Function
This is the only medication I've taken that has helped with the stiffness I've been experiencing, since Vioxx.
4.3Patient Review
9/22/2018
Nabumetone for Rheumatoid Arthritis
This medication helps me a lot with pain. It kicks in pretty quickly, which is great.
3.7Patient Review
12/3/2015
Nabumetone for Joint Damage causing Pain and Loss of Function
The medicine worked great at first, but then its effectiveness decreased after five months. Now I get headaches and blurred vision from taking it, so I have to stop. Not sure what my next plan of action will be for pain management.
2.3Patient Review
2/22/2018
Nabumetone for Joint Inflammatory Disease in Children and Young Adults
I didn't love this medication because it seemed to weaken my leg muscles and give me more pain at night.
2Patient Review
1/3/2016
Nabumetone for Rheumatoid Arthritis
I developed a rash and started experiencing headaches after taking this medication for about a month. I will be contacting my doctor in the morning to discuss these side effects.
1.7Patient Review
5/17/2022
Nabumetone for Joint Damage causing Pain and Loss of Function
The side effects of this medication were way too severe for me, unfortunately. I had intestinal upset and heart palpitations that made me feel very anxious. The dizziness was also a problem. It did help with the pain in my body, but I couldn't handle the negative impacts
1.7Patient Review
10/20/2022
Nabumetone for Joint Damage causing Pain and Loss of Function
NABUMETONE 500 MG was unfortunately giving me constant diarrhea.
1Patient Review
6/11/2017
Nabumetone for Rheumatoid Arthritis
This worked for a little while, but never completely took the pain away. I stopped taking it after two months and have not experienced an increase in pain since then.
1Patient Review
10/21/2017
Nabumetone for Joint Damage causing Pain and Loss of Function
I was given this medication for my herniated discs and sciatica. Unfortunately, I had a terrible reaction to it and ended up unconscious for several hours. When I woke up, I still felt very woozy and my pain was no better.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about nabumetone

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is nabumetone a pain killer?

"Nabumetone is used to reduce pain, swelling, and joint stiffness caused by arthritis. This medication belongs to a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). If you have a chronic condition such as arthritis, your doctor may recommend nonsurgical treatments and/or other medications to treat your pain."

Answered by AI

Is nabumetone a strong painkiller?

"Both nabumetone and ibuprofen are effective drugs to relieve pain when used as prescribed. They have been approved by FDA to treat pain and inflammation caused by arthritis. The best NSAID to use is the one that is most effective for your specific condition and symptoms."

Answered by AI

What is nabumetone used for?

"Nabumetone is a nonsteroidal anti-inflammatory drug that can be used to relieve mild to moderate pain caused by conditions like osteoarthritis and rheumatoid arthritis. It can help reduce inflammation, swelling, stiffness, and joint pain. The earliest date this drug can be used is June 1, 2022."

Answered by AI

What are the side effects of nabumetone 500 mg?

"If you experience any of the following symptoms, you may be experiencing a reaction to sugar alcohol: diarrhea, constipation, gas or bloating, dizziness, headache, dry mouth, sores in the mouth, or nervousness."

Answered by AI

Clinical Trials for Nabumetone

Image of California Clinical Trials Medical Group in Glendale, United States.

NTR-1011 for Lupus and Rheumatoid Arthritis

18 - 75
All Sexes
Glendale, CA
This phase 1a and 1b study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of NTR-1011 in healthy adults and in adult patients with systemic lupus erythematosus and rheumatoid arthritis. The main goals of this study are to determine the safety profile of NTR-1011 across subcutaneous and intravenous dose levels, understand how the drug behaves in the body, characterize its biological activity through relevant pharmacodynamic markers, assess the potential for immune responses to treatment, and explore early signals of clinical benefit in autoimmune disease settings. This is a randomized, double blind, placebo controlled study that begins with a single ascending dose evaluation in healthy volunteers followed by a multiple dose assessment in patients. The design is intended to define the highest safe and well tolerated dose, establish a robust PK and PD baseline, and generate initial patient level evidence to support dose selection and advancement into subsequent clinical development.
Phase 1
Recruiting
California Clinical Trials Medical GroupHakop Gevorkyan, MDNeutrolis
Image of Weill Cornell Medical College in New York, United States.

Health Coaching for Rheumatoid Arthritis

18+
All Sexes
New York, NY
The goal of this clinical trial is to learn if peer coaching works to reduce levels of anxiety and/or depression in adults diagnosed with Rheumatoid Arthritis (RA). The main questions it aims to answer are: Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months from baseline? Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months compared to those in the control arm? Researchers will compare the peer coaching intervention to an active-control arm (where people without RA coach participants on general health and nutrition topics) to see if peer coaching works to reduce anxiety and/or depression. Participants will meet with a coach every week for 9 weeks and complete several surveys before, during and after the intervention
Recruiting
Has No Placebo
Weill Cornell Medical CollegeIris Y Navarro-Millán, MDBristol-Myers Squibb
Image of Humana Healthcare Research, Inc. in Louisville, United States.

Academic Detailing for Rheumatoid Arthritis

Any Age
All Sexes
Louisville, KY
The goal of this trial is to learn if an interactive evidence-based educational outreach visits to clinicians who prescribe biologics change prescribing of biosimilar medications. The main questions it aims to answer are: 1. Do educational outreach visits lead to a higher number of prescriptions for biosimilar versions of adalimumab? 2. Do in-person or virtual visits work better? Researchers will compare clinicians offered the educational outreach visit to those who are not offered the visit to see if there is a difference in prescribing of biosimilar versions of adalimumab instead of the original brand-name version. Participants will be offered the chance to meet with a trained clinician who will provide educational information tailored to their knowledge and attitudes on the topic. They will also be provided an educational brochure and patient educational materials.
Waitlist Available
Has No Placebo
Humana Healthcare Research, Inc. (+1 Sites)
Image of Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016) in New York, United States.

Electromagnetic Resonance Therapy for Autoimmune Diseases

Any Age
All Sexes
New York, NY
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with each other. The goal is to see if this "quantum-synaptic" signaling effect can help stabilize immune activity and reduce the number of autoimmune flare-ups in people living with conditions such as lupus, rheumatoid arthritis, or multiple sclerosis. Participants will receive either an active or a sham (placebo) LF-EMR session three times per week for twelve weeks. Each session is completely non-invasive. Blood samples will be collected to study cytokines (immune-system messenger molecules), gene-expression patterns, and electrical field coherence among immune cells. A machine-learning system will analyze these data to predict inflammation patterns and guide individualized treatment settings. All participant data will be securely recorded and time-stamped to ensure transparency and privacy. The expected outcome of the study is a measurable reduction in autoimmune flare frequency and symptom severity, along with improved understanding of how electromagnetic signaling might safely regulate immune function.
Phase 1 & 2
Waitlist Available
Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016)Gavin Solomon, President & CEOTruway Health, Inc.
Have you considered Nabumetone clinical trials? We made a collection of clinical trials featuring Nabumetone, we think they might fit your search criteria.Go to Trials
Image of St. Lawrence Health in Potsdam, United States.

Primary Care for Rheumatoid Arthritis

18+
All Sexes
Potsdam, NY
Rheumatoid arthritis (RA) is a complex autoimmune disease where the immune system attacks healthy joint tissue; causing pain, swelling, and stiffness of the joints. This disease effects lots of people in the US and can lead to major joint damage if not properly treated. In rural areas like northern NY, these are underserved areas for RA patients, thus many patients struggle to get the appropriate care. This model is testing whether primary care providers (PCP) can safely and effectively provide stable RA patients with the proper treatment rather than send them to a specialist. PCPs were trained through classes, case reviews, and a final exam. Patients will be randomly assigned to either see a trained PCP or their normal rheumatologist at the rheumatology clinic. This study will examine how patients are doing over a year using medical exams and patient feedback. If this model proves to be successful, it will make RA treatment easier and more affordable for patients.
Recruiting
Has No Placebo
St. Lawrence HealthEyal Kedar, MD
Image of Pender Community Health Centre in Vancouver, Canada.

Personalized Outreach for Rheumatic Diseases

18+
All Sexes
Vancouver, Canada
The primary goal of this study is to determine whether providing patient honoraria and/or outreach services can improve the attendance rate of appointments at an inner city rheumatology clinic in Vancouver, British Columbia. The main question it aims to answer are: * Does providing a financial honorarium ($20 for each follow-up appointment with completed bloodwork) improve attendance rate at an inner city rheumatology clinic? * Does providing a personalized outreach service for rheumatic diseases improve attendance rate at an inner city rheumatology clinic? The researchers will compare providing patient honoraria to providing both honoraria and outreach services, and compare each of these to the regular appointment schedule without honoraria or outreach. Participants will: * Undergo randomization to receive honoraria or honoraria and outreach services together * Complete surveys about their health and understanding of their rheumatic disease at baseline, 3-month, and 6-month intervals * Visit the clinic every month for check-ups and monitoring bloodwork if they are started on immunosuppressants for their condition
Waitlist Available
Has No Placebo
Pender Community Health CentreBrent R Ohata, MD
Have you considered Nabumetone clinical trials? We made a collection of clinical trials featuring Nabumetone, we think they might fit your search criteria.Go to Trials
Image of Clinical Research Of West Florida - Phase I Unit /ID# 272428 in Clearwater, United States.

Targeted Therapies for Rheumatoid Arthritis

18+
All Sexes
Clearwater, FL
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies for the treatment of moderately to severely active Rheumatoid Arthritis (RA). This study currently includes 3 substudies evaluating different treatments in participants with RA. Substudy 1 will evaluate lutikizumab monotherapy (treatment given alone) compared to placebo (looks like the study treatment but contains no medicine). Substudy 2 will evaluate ravagalimab monotherapy compared to placebo and Substudy 3 will evaluate lutikizumab and ravagalimab combination therapy (treatments given together) compared to placebo. Approximately 180 participants who have failed 1 or 2 biologic/targeted synthetic disease-modifying antirheumatic drug (tsDMARD) therapies will be enrolled in the study at approximately 65 sites worldwide. There may be higher treatment burden for participants in this trial compared to their standard of care treatment without participating in this study. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Phase 2
Recruiting
Clinical Research Of West Florida - Phase I Unit /ID# 272428 (+30 Sites)ABBVIE INC.AbbVie
Have you considered Nabumetone clinical trials? We made a collection of clinical trials featuring Nabumetone, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security